Hyperion: Glycerol Phenylbutyrate Phase 2 Trial Meets Primary Endpoint

(RTTNews) - Hyperion Therapeutics, Inc. (HPTX) announced the publication of the results of Phase 2 trial of glycerol phenylbutyrate for the treatment of hepatic encephalopathy. The study met its primary endpoint with significantly fewer patients treated with glycerol phenylbutyrate experiencing hepatic encephalopathy events as compared to patients receiving placebo.

The randomized, double-blind, placebo-controlled Phase 2 trial enrolled 178 patients with cirrhosis, including 59 already taking rifaximin, who had experienced two or more hepatic encephalopathy events in the prior six months.